CeriBell (NASDAQ:CBLL) (NASDAQ:CBLL) is a medical technology company specializing in non-invasive point-of-care ultrasound solutions for obstetric and gynecologic applications. Founded in 2016 and headquartered in Wayne, Pennsylvania, the company leverages proprietary imaging hardware and cloud-based analytics to support clinicians in prenatal monitoring, women’s health diagnostics, and maternal-fetal care. CeriBell’s systems are designed to deliver rapid, real-time insights at the bedside, reducing reliance on centralized imaging facilities and streamlining patient workflows.
The company’s flagship offering, the CeriScan Point-of-Care Ultrasound System, integrates advanced transducer technology with software algorithms for automated image capture and analysis. Key functional capabilities include biometric measurements, fetal heart rate assessment, and uterine activity monitoring. By combining compact, handheld devices with secure data transmission, CeriBell enables remote interpretation and telehealth collaboration, helping providers make informed decisions during routine prenatal visits, labor management and high-risk screenings.
CeriBell markets its products primarily in North America, with ongoing expansion efforts in Europe and Latin America. The firm partners with hospitals, outpatient clinics and telemedicine networks to broaden adoption of point-of-care ultrasound in both urban and underserved regions. In addition to clinical deployments, CeriBell collaborates with academic institutions on research initiatives aimed at enhancing maternal and neonatal outcomes through early detection of complications such as fetal distress, placental insufficiency and preterm labor.
Led by Chief Executive Officer Rohit Bhalla, CeriBell’s management team combines expertise in medical imaging, regulatory affairs and global commercialization. The Board of Directors includes seasoned executives from the healthcare and technology sectors, guiding the company’s strategy to innovate diagnostic tools that advance women’s health. As CeriBell continues to develop new applications and expand its footprint, it remains focused on improving access to quality prenatal care and elevating clinical decision-making at the point of care.
